Loading viewer...
investor_presentation
Format: PDF investor_presentation
Xenetic Biosciences presents its DNase I oncology platform technology aimed at improving cancer immunotherapies by targeting neutrophil extracellular traps (NETs). The proprietary enzyme digests DNA to expose cancer cells and overcome resistance to chemotherapy and checkpoint inhibitors across multiple high-value cancer indications including pancreatic cancer.
presentation
investor_presentation
15 Pages
G5 Entertainment
Adani Energy Solutions Limited Investor Presentation January 2024
investor_presentationinvestor_presentation
55 Pages
Adani Energy Solutions Limited
Pacific Life Global Funding II Q2 2023 Investor Presentation
investor_presentationinvestor_presentation
35 Pages
Pacific Life Insurance Company